Texas Permanent School Fund Buys 1,317 Shares of RadNet, Inc. (NASDAQ:RDNT)

Texas Permanent School Fund boosted its stake in shares of RadNet, Inc. (NASDAQ:RDNTGet Rating) by 3.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,919 shares of the medical research company’s stock after acquiring an additional 1,317 shares during the period. Texas Permanent School Fund’s holdings in RadNet were worth $711,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC increased its stake in shares of RadNet by 180.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,443 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 2,217 shares during the last quarter. First Manhattan Co. bought a new position in shares of RadNet in the 1st quarter valued at $82,000. Captrust Financial Advisors increased its stake in shares of RadNet by 54.0% in the 1st quarter. Captrust Financial Advisors now owns 4,123 shares of the medical research company’s stock valued at $92,000 after purchasing an additional 1,446 shares during the last quarter. Mutual of America Capital Management LLC increased its stake in shares of RadNet by 16.7% in the 2nd quarter. Mutual of America Capital Management LLC now owns 7,837 shares of the medical research company’s stock valued at $135,000 after purchasing an additional 1,119 shares during the last quarter. Finally, BNP Paribas Arbitrage SA increased its stake in shares of RadNet by 9.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,149 shares of the medical research company’s stock valued at $227,000 after purchasing an additional 1,147 shares during the last quarter. Institutional investors own 68.27% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on RadNet in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock.

Insider Buying and Selling

In related news, Director Christine Nayoma Gordon sold 3,000 shares of the business’s stock in a transaction on Monday, December 19th. The stock was sold at an average price of $19.57, for a total transaction of $58,710.00. Following the sale, the director now owns 9,497 shares in the company, valued at approximately $185,856.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other RadNet news, COO Norman R. Hames sold 5,000 shares of RadNet stock in a transaction dated Monday, December 19th. The stock was sold at an average price of $19.45, for a total transaction of $97,250.00. Following the transaction, the chief operating officer now directly owns 275,179 shares of the company’s stock, valued at approximately $5,352,231.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christine Nayoma Gordon sold 3,000 shares of RadNet stock in a transaction dated Monday, December 19th. The stock was sold at an average price of $19.57, for a total value of $58,710.00. Following the transaction, the director now directly owns 9,497 shares in the company, valued at $185,856.29. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by corporate insiders.

RadNet Trading Up 2.0 %

Shares of RDNT stock opened at $20.00 on Friday. The firm has a market capitalization of $1.15 billion, a P/E ratio of 166.68 and a beta of 1.54. RadNet, Inc. has a twelve month low of $12.03 and a twelve month high of $28.22. The company has a quick ratio of 0.79, a current ratio of 0.79 and a debt-to-equity ratio of 1.60. The stock’s fifty day simple moving average is $18.60 and its 200 day simple moving average is $19.35.

RadNet (NASDAQ:RDNTGet Rating) last issued its quarterly earnings data on Wednesday, November 9th. The medical research company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.07). The firm had revenue of $350.04 million for the quarter, compared to the consensus estimate of $350.17 million. RadNet had a return on equity of 2.98% and a net margin of 0.56%. As a group, sell-side analysts predict that RadNet, Inc. will post 0.31 EPS for the current fiscal year.

About RadNet

(Get Rating)

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Articles

Want to see what other hedge funds are holding RDNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RadNet, Inc. (NASDAQ:RDNTGet Rating).

Institutional Ownership by Quarter for RadNet (NASDAQ:RDNT)

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.